What Is the Difference Between Biosimilarity and Interchangeability for Biosimilar Products?
Introduction The primary Difference Between Biosimilarity and Interchangeability lies in regulatory designation and pharmacy-level substitution rights rather than any variation
Biosimilar Functional Bioassay Development Service: Cell-Based and Binding Assays for Regulatory Dossiers
Introduction A specialized Biosimilar Functional Bioassay Development Service provides Mechanism of Action (MoA)-reflective cell-based and binding assays that are specifically
Disulfide Bond Mapping Service for Biosimilars: LC-MS Approaches and Regulatory Compliance
Introduction Establishing structural equivalence through a specialized Disulfide Bond Mapping Service for Biosimilars is critical for verifying higher-order structural integrity,
Case Study: Forced Degradation and Stress Testing to Predict Stability Risks in a Bevacizumab Biosimilar Programme
Introduction: Developing a biosimilar monoclonal antibody involves far more than demonstrating analytical similarity with the reference product. One of the
Biosimilar Interchangeability Designation in the USA: FDA Requirements and What It Means for Market Access
Introduction The Biosimilar Interchangeability Designation in the USA represents a significant legal and regulatory framework established under the Biologics Price
Generic Drug vs Biosimilar: What Is the Difference and How Does CDMO Support Differ?
Introduction The distinction between a Generic Drug vs Biosimilar forms the core scientific and regulatory boundary separating chemically synthesized small-molecule
Generic Drug vs Biosimilar: What Is the Difference and How Does CDMO Support Differ? Read More »
Case Study: Resolving a Higher-Order Structure Discrepancy in an Etanercept Biosimilar Using HDX-MS
Introduction: The Etanercept Biosimilar Higher-Order Structure is one of the most critical attributes evaluated during biosimilar development because even subtle
Post-Approval Changes for Approved Biosimilars: Comparability Requirements Under ICH Q5E
Introduction Post-Approval Changes for Approved Biosimilars require a structured, science-driven comparability assessment conducted in accordance with the ICH Q5E framework
Post-Approval Changes for Approved Biosimilars: Comparability Requirements Under ICH Q5E Read More »